Table 2 Mendelian Randomization estimates of Probucol’s effect on Behçet’s disease.

From: Mendelian randomization reveals probucol’s preventive role in Behçet’s disease via circulating metabolites

Exposure

Outcome

Nsnp

Method

MR

Heterogeneity

Horizontal pleiotropy

Drug_OR (95%CI)

P value

I2 (%)

Cochran’s Q

P-value

Egger intercept

SE

P-value

MR-PRESSO global test p

ABCA1 inhibitor

Behcet’s disease

30

MR Egger

0.5648 (0.1006–3.1702)

0.5216

0

23.4880

0.7083

0.0172

0.1097

0.8764

0.7610

Weighted median

0.4233 (0.1867–0.96)

0.0396

0.7610

Inverse variance weighted

0.4957 (0.283–0.8681)

0.0141

0

23.5126

0.7526

0.7610

Simple mode

0.4539 (0.1285–1.6032)

0.2297

0.7610

Weighted mode

0.4207 (0.1707–1.0369)

0.0700

0.7610

  1. CI, confidence interval; OR, odds ratio; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier.